Genzyme
American biotechnology company known for pioneering enzyme-replacement and other treatments for rare diseases; acquired by Sanofi in 2011 and integrated into Sanofi's corporate brand in 2022.
Last updated October 14, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Genzyme was an American biotechnology company established in 1981 in the Boston area and later headquartered in Cambridge, Massachusetts. It developed from a small enterprise focused on diagnostic and industrial enzymes into one of the world's major biotechnology companies, with a particular reputation for therapies addressing rare inherited disorders and other diseases with limited treatment options. The company was founded by Sheridan Snyder and George M. Whitesides. Its early development was supported by venture capital and a series of acquisitions, including Whatman Biochemicals and Koch-Light Laboratories. Henri Termeer joined as president in 1983 and redirected the business toward modified enzymes intended for human therapeutic use. Termeer became chief executive in 1985, took the company public in 1986, and led its transformation into a diversified biotechnology group. Genzyme's defining breakthrough came in the treatment of Gaucher disease, a lysosomal storage disorder caused by deficiency of an important enzyme. Ceredase, an enzyme-replacement therapy derived from human placental tissue, received U.S. approval in 1991. Cerezyme, a recombinant version, was approved in 1994 and became the company's best-known product. The Gaucher franchise demonstrated that medicines for very small patient populations could support substantial research, manufacturing, and commercial operations, helping establish the modern commercial model for orphan drugs. The products also attracted criticism because of their high annual treatment costs. During the 1990s and 2000s, Genzyme expanded through acquisitions and internal development. It built businesses in renal medicine, transplantation and immunology, oncology, molecular diagnostics, genetics, orthopedics, and surgical products. Important medicines and franchises included Renagel for phosphate control in dialysis patients, Fabrazyme for Fabry disease, and Thymoglobulin for transplant-related immune management. The company also developed or acquired capabilities in genetic testing, biologics manufacturing, biomaterials, and cancer diagnostics. Genzyme was a substantial international operator by the late 2000s. It maintained manufacturing and laboratory facilities in the United States and Europe, sold products in many countries, and operated across several specialized medical areas. In 2007, the company reported approximately $3.8 billion in revenue and more than 25 products on the market. Around 2010, it employed more than 11,000 people and generated roughly $4 billion in revenue, with enzyme therapies representing a significant share of the business. It was also recognized for workplace practices and philanthropic product donations, including large donations of medicines to patients and health systems worldwide. The company experienced serious manufacturing and supply problems in 2008–2010. Viral contamination affected facilities in Geel, Belgium, and Allston, Massachusetts, while quality defects involving foreign materials were found in some products. Production interruptions contributed to shortages and rationing of Fabrazyme and constrained supplies of Cerezyme. Regulators allowed certain products to remain available because of the absence of reported adverse events and the lack of readily available alternatives, but the events damaged confidence and increased pressure on Genzyme's operations. Sanofi announced an unsolicited approach for Genzyme in 2010. After negotiations and an extended dispute over valuation, Sanofi completed the acquisition in 2011 for approximately $20.1 billion. Genzyme continued for years as a wholly owned Sanofi subsidiary and served as the group's principal rare-disease and specialty-care identity. In February 2022, Sanofi introduced a unified corporate brand and folded the former Sanofi Genzyme identity into Sanofi. The Genzyme name therefore remains historically important and may continue to appear in product, scientific, manufacturing, or legacy refe…
History
Genzyme began in 1981 when Sheridan Snyder and George M. Whitesides established a biotechnology venture in the Boston area. Its scientific origins were connected to Henry Blair, a technician at Tufts Medical School's New England Enzyme Center who had worked under a National Institutes of Health contract to produce modified enzymes for clinical research. The company's first office was a converted clothing warehouse near Tufts. Early expansion was acquisition-led. Genzyme bought Whatman Biochemicals in 1981 and Koch-Light Laboratories in 1982, broadening its access to biochemical products and diagnostic materials. Henri Termeer joined as president in 1983. Under his direction, Genzyme moved away from being primarily a supplier of diagnostic enzymes and concentrated on enzymes that could replace deficient human proteins. Termeer became chief executive in 1985, and Genzyme completed an initial public offering in 1986. The company strengthened its molecular biology and diagnostics capabilities through the 1989 acquisition of Integrated Genetics. Its major therapeutic turning point followed in 1991, when the U.S. Food and Drug Administration approved Ceredase for Gaucher disease. Gaucher disease is a rare inherited condition in which deficient enzyme activity causes harmful accumulation of fatty substances in organs and tissues. Ceredase became an important commercial and scientific milestone: it was among the first successful enzyme-replacement treatments for a rare genetic disorder. Genzyme later introduced Cerezyme, a recombinant version approved in 1994, which became the principal product of the franchise. Genzyme expanded throughout the 1990s by purchasing or developing businesses in immunodiagnostics, genetic testing, oncology, and surgical products. Acquisitions included Medix Biotech, Enzymatix, Vivigen, Virotech, Omni Res, Sygena, BioSurface Technology, and TSI. Genzyme Molecular Oncology was created after the 1997 acquisition of PharmaGenics, while Genzyme Surgical Products was established in 1999. The 2000s brought further diversification. Genzyme announced the acquisition of Biomatrix and later bought SangStat Medical, bringing the transplant medicine Thymoglobulin into the portfolio. It acquired Ilex Oncology, selected laboratories and cancer-testing technologies from Impath after that company's bankruptcy filing, Bone Care International, and AnorMED. In 2007, Genzyme agreed to acquire Bioenvision, motivated in part by the leukemia medicine clofarabine, marketed in North America as Clolar. These moves expanded the company beyond enzyme replacement into renal care, transplantation, oncology, and specialty pharmaceuticals. Genzyme's growth was accompanied by a strong rare-disease orientation. The company developed medicines for conditions with small patient populations and high clinical need, while also maintaining diagnostic laboratories and manufacturing infrastructure. It received recognition for workplace policies and philanthropic activity, including substantial donations of medicines and cash. The company was awarded the U.S. National Medal of Technology in 2005. Manufacturing problems became a defining issue at the end of the decade. A viral contamination incident affected the Geel, Belgium facility in 2008, and a related contamination event forced the Allston, Massachusetts plant to close in 2009. Genzyme also found foreign particulate matter in certain medicines. Restarted production operated below normal capacity, contributing to shortages of Cerezyme and Fabrazyme. Fabrazyme distribution was rationed, and patients and advocacy groups pressed for measures that could increase supply. The events led to regulatory scrutiny and operational remediation. In 2010, Genzyme sold its genetics business to Laboratory Corporation of America for approximately $925 million. That same year, Sanofi launched a bid for Genzyme. The initial offer was rejected, but the companies eventually reached an agreement. Sanofi completed the acquisition in 2011 for approximately $20.1 billion. Genzyme then operated as a wholly owned Sanofi subsidiary, later using the Sanofi Genzyme identity for rare diseases and specialty care. In 2022, Sanofi retired the separate corporate branding as part of a group-wide rebrand and integrated Sanofi Genzyme into Sanofi. Genzyme is consequently best understood today as a major historical biotechnology brand and a legacy identity within Sanofi rather than as an independent listed company.
- 2022
Legacy brand integrated into Sanofi
[1]Sanofi ended the separate Sanofi Genzyme corporate identity as part of a unified global rebrand.
- 2011
Acquired by Sanofi
[1]Sanofi completed its acquisition of Genzyme for approximately $20.1 billion.
- 2010
Genzyme Genetics sold
[1]The genetics business was sold to Laboratory Corporation of America.
- 2009
Allston manufacturing shutdown
[1]The Allston facility was closed temporarily after a viral contamination event.
- 2007
Bioenvision acquisition agreed
[1]Genzyme agreed to acquire Bioenvision, including North American rights associated with clofarabine.
- 2005
National Medal of Technology awarded
[1]Genzyme received the U.S. National Medal of Technology for innovation.
- 2003
SangStat Medical acquired
[1]Genzyme acquired SangStat and its transplant medicine Thymoglobulin.
- 1994
Cerezyme approved
[1]The recombinant enzyme-replacement therapy replaced Ceredase as the leading Gaucher disease product.
- 1991
Ceredase approved
[1]Ceredase became the first FDA-approved Genzyme therapy for Gaucher disease.
- 1989
Integrated Genetics acquired
[1]The acquisition strengthened Genzyme's capabilities in molecular biology, protein chemistry, and diagnostics.
Products and positioning
Specialty biopharmaceutical company centered on rare diseases, enzyme-replacement therapies, and other high-complexity treatments for underserved patient populations.
Enzyme-replacement therapy · 1991
Ceredase
Ceredase was Genzyme's pioneering treatment for Gaucher disease and one of the earliest commercially successful enzyme-replacement therapies for a rare inherited disorder. It used a form of glucocerebrosidase to compensate for deficient enzyme activity and reduce the accumulation of harmful material in organs and tissues. The product established Genzyme's long-term focus on rare diseases, although its high annual treatment cost drew public criticism.
Enzyme-replacement therapy · 1994
Cerezyme
Cerezyme is a recombinant form of glucocerebrosidase used as enzyme-replacement therapy for Gaucher disease. Approved in 1994, it became Genzyme's principal successor to Ceredase and its most recognized product. The therapy exemplified the company's strategy of developing biologic medicines for rare, serious genetic conditions. Production disruptions in the late 2000s caused supply constraints and prompted regulatory and patient scrutiny.
Enzyme-replacement therapy
Fabrazyme
Fabrazyme is an enzyme-replacement treatment for Fabry disease, a rare lysosomal storage disorder. It supplies recombinant alpha-galactosidase A to address the enzyme deficiency underlying the disease. Fabrazyme became one of Genzyme's important rare-disease products, but manufacturing problems around 2009 and 2010 led to supply rationing and reduced dosing availability for patients.
Renal medicine
Renagel
Renagel was a phosphate-binding medicine used in patients with chronic kidney disease receiving dialysis. It addressed the elevated phosphate levels that can accompany renal failure and represented Genzyme's expansion beyond lysosomal storage diseases into chronic renal care. The product became one of the company's significant non-enzyme therapeutic franchises.
Transplant and immunology medicine
Thymoglobulin
Thymoglobulin is an immunosuppressive biologic used in transplantation and related immune-management settings. Genzyme obtained the product through its 2003 acquisition of SangStat Medical. It broadened the company's specialty-care portfolio and complemented its presence in transplant medicine and immunology.
Oncology medicine
Clolar
Clolar is the North American commercial name associated with clofarabine, an oncology medicine for certain forms of leukemia. Genzyme obtained relevant commercial rights through its relationship with Bioenvision and pursued the acquisition of Bioenvision in 2007. The product reflected the company's effort to extend its specialty-biopharmaceutical model into oncology.
Surgical biomaterial
Seprafilm
Seprafilm is an adhesion-barrier product used in surgery to reduce the formation of postoperative adhesions. It belonged to Genzyme's surgical-products activities rather than its core rare-disease medicines. The product became the subject of U.S. enforcement actions after allegations that sales representatives promoted an unapproved method of preparing and using it during laparoscopic procedures.
Controversies
2015
Seprafilm off-label marketing settlement
Genzyme accepted responsibility and agreed to pay approximately $32.59 million to resolve U.S. allegations concerning promotion of an unapproved laparoscopic slurry application of Seprafilm. A separate civil agreement related to the marketing allegations had been reached in 2013.
2009
Manufacturing contamination and product-quality failures
Viral contamination at Genzyme facilities in Belgium and Massachusetts, together with foreign material found in some drug batches, caused shutdowns, reduced output, and shortages of important medicines. Regulators permitted some products to remain available because patients had few alternatives, but the incidents generated significant scrutiny.
Marketing campaigns
- 2006Workplace and social-impact recognition
United States · Global
Genzyme's corporate reputation program emphasized employee culture, patient access, and philanthropy. The company was recognized by Fortune as one of the best companies to work for in 2006 and 2007, and it reported major donations of medicines and cash to patients and communities.
Outcome. The activity supported Genzyme's public positioning as a patient-oriented biotechnology company.
Brand decisions
2022
Integration into Sanofi's unified brandStrategyBackground
Sanofi introduced a new corporate branding system intended to present the group under one principal identity.
Action taken
The former Sanofi Genzyme identity was folded into Sanofi.
Aftermath
Genzyme ceased to function as Sanofi's primary standalone corporate brand, although the name remains relevant as a historical and legacy operating identity.
2011
Acquisition by SanofiM&ABackground
Genzyme had become a major rare-disease and specialty-biopharmaceutical business with global products and manufacturing capabilities.
Action taken
Sanofi completed the acquisition and operated Genzyme as a wholly owned subsidiary.
Aftermath
Genzyme continued as a specialized Sanofi business before the separate Sanofi Genzyme identity was integrated into Sanofi in 2022.
Acquisition value. (2011)
2010
Sale of Genzyme GeneticsStrategyBackground
Genzyme was simplifying its portfolio while managing manufacturing problems and preparing for strategic discussions with potential acquirers.
Action taken
The company sold Genzyme Genetics to Laboratory Corporation of America for approximately $925 million.
Aftermath
The transaction separated the genetics-testing business from the therapeutic operations that became the principal focus of Sanofi's acquisition.
Sale value. (2010)
2010
Sanofi takeover proposalM&ABackground
Sanofi sought to expand its presence in rare diseases and specialty medicines, while Genzyme's board initially viewed the proposed valuation as inadequate.
Action taken
Sanofi announced an approximately $18.5 billion offer, which Genzyme rejected before the parties reached a later agreement.
Aftermath
The process culminated in Sanofi's acquisition of Genzyme for approximately $20.1 billion in 2011.
Initial acquisition offer. (2010)
1991
Launch of CeredaseProduct launchBackground
Gaucher disease had been a rare and potentially fatal condition with no effective approved treatment.
Action taken
Genzyme commercialized Ceredase as an enzyme-replacement therapy after U.S. approval.
Aftermath
The product established Genzyme as a leading rare-disease biotechnology company while also prompting debate over the cost of treatment.
1983
Shift from diagnostic enzymes to therapeutic enzymesStrategyBackground
Under Henri Termeer, Genzyme sought to move beyond diagnostic and industrial enzyme activities toward modified enzymes that could replace deficient human proteins.
Action taken
The company prioritized research and commercialization in rare inherited disorders, laying the foundation for its orphan-drug business.
Aftermath
This strategy produced the Ceredase and Cerezyme Gaucher disease franchise and became central to Genzyme's identity.
Recent events
Reported
Sanofi unveils new corporate brand and logo[3]
Sanofi unveiled a new corporate brand and logo, bringing its business units Sanofi Pasteur and Sanofi Genzyme, along with other acquired brands, under the singular Sanofi name and brand.
Reported
FDA approves Nexviazyme for late-onset Pompe disease[4]
The U.S. Food and Drug Administration approved Genzyme Corporation's Nexviazyme for treatment of patients aged 1 year and older with late-onset Pompe disease.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/genzyme · Editorial policy · How profiles are compiled